Technetium (99mTc) albumin aggregated

Technetium (99mTc) Albumin Aggregated

File:Technetium-99m generator.jpg

Technetium-99m generator

Technetium (99mTc) albumin aggregated, also known as Tc-99m MAA, is a radiopharmaceutical used in nuclear medicine imaging procedures. It consists of technetium-99m (99mTc) labeled to aggregated human serum albumin particles. This radiopharmaceutical is primarily used for lung perfusion imaging, also known as lung scan or ventilation-perfusion (V/Q) scan.

Production

Technetium-99m is produced from a molybdenum-99 (99Mo)/technetium-99m generator system. The generator contains a column of 99Mo, which decays to 99mTc. The 99mTc is then eluted from the generator using a saline solution. The eluate is then mixed with a vial containing aggregated human serum albumin particles, resulting in the formation of Tc-99m MAA.

Mechanism of Action

Once administered intravenously, Tc-99m MAA particles are trapped in the pulmonary capillaries due to their size. These particles are too large to pass through the capillary bed and get lodged in the lung vasculature. The distribution of the particles reflects the perfusion of blood in the lungs.

Clinical Applications

Tc-99m MAA is primarily used for lung perfusion imaging in the evaluation of pulmonary embolism (PE). PE occurs when a blood clot or other material blocks one or more arteries in the lungs. Lung perfusion imaging helps in the diagnosis and assessment of the extent of PE.

The procedure involves the injection of Tc-99m MAA into a peripheral vein. The patient is then positioned under a gamma camera, which detects the gamma radiation emitted by the radiopharmaceutical. Images are acquired in multiple projections to obtain a comprehensive view of the lung perfusion.

Advantages

Tc-99m MAA has several advantages over other imaging modalities for lung perfusion assessment. It provides high-resolution images, allowing for the detection of small emboli. It is also a non-invasive procedure, minimizing patient discomfort and risk. Additionally, Tc-99m MAA has a short half-life (approximately 6 hours), reducing radiation exposure to the patient.

Safety Considerations

Tc-99m MAA is generally safe and well-tolerated. However, as with any radiopharmaceutical, there are some potential risks and side effects. These include allergic reactions, injection site reactions, and rare instances of pulmonary embolism caused by the radiopharmaceutical itself. Proper patient selection, administration, and monitoring protocols are essential to minimize these risks.

Conclusion

Technetium (99mTc) albumin aggregated (Tc-99m MAA) is a valuable radiopharmaceutical used in lung perfusion imaging for the evaluation of pulmonary embolism. It provides high-resolution images and is a safe and effective diagnostic tool. With proper administration and monitoring, Tc-99m MAA plays a crucial role in the management of patients with suspected PE, aiding in accurate diagnosis and appropriate treatment planning.

Technetium (99mTc) albumin aggregated Resources
Latest articles Most recent articles Ongoing trials	Wikipedia